Factors Associated With Altmetric Attention Scores for Randomized Phase III Cancer Clinical Trials

被引:0
|
作者
Rooney, Michael K. [1 ]
Sharifi, Bahareh [1 ]
Ludmir, Ethan B. [1 ]
Fuller, Clifton D. [1 ]
Warner, Jeremy L. [2 ,3 ,4 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX USA
[2] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA
[3] Lifespan Canc Inst, Providence, RI USA
[4] Brown Univ, 231 Elmgrove Ave,PRB 777, Providence, RI 02906 USA
来源
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Altmetric Attention Scores (Altmetrics) are real-time measures of scientific impact and attention through various public outlets, including news, blogs, and social media. Herein, we aimed to describe and characterize the relationship between Altmetrics, conventional impact metrics, and features of published cancer clinical trials.METHODS We identified two-arm phase III cancer randomized clinical trials with a superiority end point and publication date between 2015 and 2020 from HemOnc and tabulated the following data: Altmetric, study positivity, US Food and Drug Administration (FDA) registration trial status, cancer site/category, treatment context (curative or palliative), trial design, primary end point type, experimental/control arm modality, and journal tier. We further collected conventional bibliometrics including the number of citations and relative citation ratio (RCR) for all published studies. Multiple linear regression modeling identified clinical trial factors predictive of Altmetrics, with alpha = .05 defining statistical significance.RESULTS Altmetrics were found for 681 (98%) of 698 publications, with a median score of 38.5 (IQR, 13-132.8). FDA registration studies (beta [95% CI], 84.7 [48.8 to 120.6]; P < .001), studies reporting on curative (as opposed to palliative) interventions (-29 [-53.7 to -4.4]; P = .02), genitourinary trials (73.2 [28.1 to 118.2]; P = .001), studies published in tier 1 journals (P < .001), and those with an increased number of citations per year (0.81 [0.66 to 0.95]; P < .001) were significantly associated with increased engagement as measured by Altmetrics. Furthermore, there was a strong correlation between all collected bibliometrics and Altmetrics (R2 = 0.63, 0.68, and 0.67; P < .001 for citation count, citations per year, and RCR, respectively).CONCLUSION FDA registration trials describing curative interventions, studies published in traditionally defined high-impact journals, and genitourinary trial publications tend to have the greatest Altmetrics. We observed a strong relationship between Altmetrics and conventional bibliometrics. The significance and consequences of these relationships warrant further investigation.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Factors associated with successful phase III trials for solid tumors: A systematic review
    Otsuka, Yasushi
    Kaneko, Masayuki
    Narukawa, Mamoru
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2021, 24
  • [42] Current phase II and phase III clinical trials for pancreatic cancer - Referral resource
    Mooney, MM
    Schoenfeldt, M
    [J]. ONCOLOGY-NEW YORK, 2004, 18 (08): : 1008 - +
  • [43] RANDOMIZED PHASE II CLINICAL TRIALS
    Jung, Sin-Ho
    Sargent, Daniel J.
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2014, 24 (04) : 802 - 816
  • [44] Role of immunotherapy in gastroesophageal cancer with liver metastasis: A meta-analysis of phase III randomized clinical trials.
    Bawek, Sawyer
    Gurusinghe, Sayuri
    Aijaz, Ali
    Attwood, Kristopher
    Mukherjee, Sarbajit
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 319 - 319
  • [45] Trends in phase III randomized controlled clinical trials on the treatment of advanced non-small-cell lung cancer
    Fernandez-Lopez, Cristina
    Exposito-Hernandez, Jose
    Pedro Arrebola-Moreno, Juan
    Angel Calleja-Hernandez, Miguel
    Exposito-Ruiz, Manuela
    Guerrero-Tejada, Rosa
    Linares, Isabel
    Cabeza-Barrera, Jose
    [J]. CANCER MEDICINE, 2016, 5 (09): : 2190 - 2197
  • [46] Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials
    Andre Esteva
    Jean Feng
    Douwe van der Wal
    Shih-Cheng Huang
    Jeffry P. Simko
    Sandy DeVries
    Emmalyn Chen
    Edward M. Schaeffer
    Todd M. Morgan
    Yilun Sun
    Amirata Ghorbani
    Nikhil Naik
    Dhruv Nathawani
    Richard Socher
    Jeff M. Michalski
    Mack Roach
    Thomas M. Pisansky
    Jedidiah M. Monson
    Farah Naz
    James Wallace
    Michelle J. Ferguson
    Jean-Paul Bahary
    James Zou
    Matthew Lungren
    Serena Yeung
    Ashley E. Ross
    Howard M. Sandler
    Phuoc T. Tran
    Daniel E. Spratt
    Stephanie Pugh
    Felix Y. Feng
    Osama Mohamad
    [J]. npj Digital Medicine, 5
  • [47] Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials
    Esteva, Andre
    Feng, Jean
    van der Wal, Douwe
    Huang, Shih-Cheng
    Simko, Jeffry P.
    DeVries, Sandy
    Chen, Emmalyn
    Schaeffer, Edward M.
    Morgan, Todd M.
    Sun, Yilun
    Ghorbani, Amirata
    Naik, Nikhil
    Nathawani, Dhruv
    Socher, Richard
    Michalski, Jeff M.
    Roach, Mack, III
    Pisansky, Thomas M.
    Monson, Jedidiah M.
    Naz, Farah
    Wallace, James
    Ferguson, Michelle J.
    Bahary, Jean-Paul
    Zou, James
    Lungren, Matthew
    Yeung, Serena
    Ross, Ashley E.
    Sandler, Howard M.
    Tran, Phuoc T.
    Spratt, Daniel E.
    Pugh, Stephanie
    Feng, Felix Y.
    Mohamad, Osama
    [J]. NPJ DIGITAL MEDICINE, 2022, 5 (01)
  • [48] Violations of the proportional hazards assumption in randomized phase III oncology clinical trials.
    Rahman, Rifaquat
    Fell, Geoffrey
    Trippa, Lorenzo
    Alexander, Brian Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Phase III randomized clinical trials global distribution and funding: Trends and disparities.
    Pinheiro, Karina
    Ribeiro, Mauricio
    Gadotti, Luiza Lara
    Marson, Fabiane
    Holanda Lopes, Carlos Diego
    Saddi, Rodrigo
    Machado Alessi, Joao Victor
    Katz, Artur
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Do Early Phase Oncology Trials Predict Clinical Efficacy in Subsequent Biomarker-Enriched Phase III Randomized Trials?
    Suji Udayakumar
    Sasha Thomson
    Albiruni R. Abdul Razak
    Kelvin K. W. Chan
    [J]. Targeted Oncology, 2022, 17 : 665 - 674